MedPath

Belite Bio, Inc.

🇺🇸United States
Ownership
Public, Subsidiary
Employees
20
Market Cap
$1.4B
Website
http://www.belitebio.com

Clinical Trials

13

Active:6
Completed:1

Trial Phases

3 Phases

Phase 1:6
Phase 2:1
Phase 3:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (50.0%)
Phase 3
5 (41.7%)
Phase 2
1 (8.3%)

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

Phase 2
Recruiting
Conditions
Stargardt Disease 1
STGD1
Interventions
Drug: Placebo
First Posted Date
2024-04-29
Last Posted Date
2025-07-16
Lead Sponsor
Belite Bio, Inc
Target Recruit Count
60
Registration Number
NCT06388083
Locations
🇺🇸

Belite Study Site - US08, Phoenix, Arizona, United States

🇺🇸

Belite Study Site - US05, La Jolla, California, United States

🇺🇸

Belite Study Site - US09, San Francisco, California, United States

and more 9 locations

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

Phase 3
Recruiting
Conditions
Geographic Atrophy
Interventions
Drug: Placebo
First Posted Date
2023-07-18
Last Posted Date
2025-02-14
Lead Sponsor
Belite Bio, Inc
Target Recruit Count
429
Registration Number
NCT05949593
Locations
🇬🇧

Belite Study Site, London, United Kingdom

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease

Phase 3
Active, not recruiting
Conditions
Stargardt Disease 1
Interventions
Drug: Placebo
First Posted Date
2022-02-17
Last Posted Date
2024-06-07
Lead Sponsor
Belite Bio, Inc
Target Recruit Count
104
Registration Number
NCT05244304
Locations
🇬🇧

Belite Study Site, Southampton, United Kingdom

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2019-07-02
Last Posted Date
2021-06-18
Lead Sponsor
Belite Bio, Inc
Target Recruit Count
40
Registration Number
NCT04005807
Locations
🇺🇸

PPD Phase I Clinic, Austin, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.